Previous Article | Next Article 
Journal of Virology, January 2000, p. 1004-1007, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Human Milk Factor Susceptible to Cathepsin D Inhibitors
Enhances Human Immunodeficiency Virus Type 1 Infectivity and Allows
Virus Entry into a Mammary Epithelial Cell Line
Kamal
El
Messaoudi,1,*
Lise F.
Thiry,1
Corinne
Liesnard,2
Nicole
Van
Tieghem,3
Alex
Bollen,1 and
Nicole
Moguilevsky1
Department of Applied Genetics, Faculty of
Science,1 Department of
Virology,2 and Department of
Microbiology,3 Faculty of Medicine,
Université Libre de Bruxelles, Brussels, Belgium
Received 14 June 1999/Accepted 30 September 1999
 |
ABSTRACT |
Human immunodeficiency virus type 1 (HIV-1) growth in lymphocyte
cultures was increased when the virus inoculum was incubated in breast
milk. The enhancing effect of milk was abolished by anti-cathepsin D
antibody or by pepstatin A, a cathepsin D inhibitor. The cathepsin
D-producing CD4-negative MCF7 mammary cells supported the growth of
some HIV-1 isolates. An MCF7 line chronically producing HIV-1 IIIb was
obtained. Cathepsin D may induce conformational modification of viral
gp120, allowing direct interaction with a coreceptor. We demonstrated
the presence of CXCR4 mRNA in MCF7 cells.
 |
TEXT |
The cell source of prolonged
production of human immunodeficiency virus type 1 (HIV-1) in breast
milk (8, 11, 21-23, 26, 27, 29) is not yet clear, since
lymphocyte counts in milk decline rapidly after delivery
(15). The risk of mother-to-child transmission through
breast-feeding has been reemphasized recently, when discontinuation of
antiretroviral therapy was followed by an increase in HIV-1 RNA load
(10, 13). Therapy withdrawal in a mother after childbirth
might also increase viral load in milk, although a short course of oral
zidovudine during the peripartum period provided an important
protection of the child despite breast-feeding (7).
We have previously shown (12) that HIV-1 variants incubated
in vaginal wash samples showed increased infectivity for lymphocyte cultures and acquired the ability to grow in a CD4-negative epithelial cell line obtained from a cervical epidermoid carcinoma. This effect
was attributed to cathepsin D, which we purified from vaginal secretions. This protease might react with the viral gp120 and modify
affinities for coreceptors.
In the present work, we found that human breast milk also enhanced the
infectivity of some HIV-1 variants. Two experiments showed that the
enhancing factor was susceptible to cathepsin D inhibitors.
Enhancing effect of milk is destroyed by inhibitors of cathepsin
D.
To demonstrate the effect of pepstatin A, an experiment was run
in two steps. Milk sample 2 or buffer was first preincubated for 10 min
at 37°C with 20 µg of pepstatin A per ml or with buffer, and these
mixtures were further incubated with HIV-1 variants before inoculation
into primary lymphocyte cultures. Milk preincubated with pepstatin A
lost its enhancing effect on HIV-1 IIIb, but enhancement was not
completely lost when the same milk sample was assayed on fresh
syncytium-inducing isolates (SI), 492 isolates, or
non-syncytium-inducing isolates (NSI), 75 isolates (Fig.
1). Chymotrypsin and trypsin inhibitors
did not modify the enhancing effect (not shown). A similar experimental
protocol was applied to study the effect of a polyclonal anti-cathepsin
D antibody on enhancing properties of milk, vaginal wash, or cathepsin
D (Table 1). Enhancement of SI 121 and
NSI 114 isolates was decreased by treatment with the anti-cathepsin D
antibody, although it was not completely abolished in some of the
mixtures. Table 2 summarizes data
obtained in various experiments and shows that the enhancement effect
of milk sample 2 on the three isolates simultaneously tested was
greater than that of milk sample 1, although this difference did not
appear in the assay of the laboratory strain, HIV-1 IIIb. A survey of
the whole table does not disclose a general trend distinguishing a
difference between SI and NSI isolates regarding their susceptibility
to milk enhancement. This table also shows the effect of various
concentrations of milk sample 2. It was striking that the final
dilution of 1:2 showed a lower enhancing effect than did the dilution
of 1:10. At higher concentrations, there may be a balance with HIV-1
inhibition caused by lactoferrin (16). In women with a
higher risk of vertical transmission of HIV to child, the serum
lactoferrin concentration is decreased (9, 25). In these
cases, the enhancing effect of the protease might dominate.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Inhibitory effect of pepstatin A on milk enhancement. As
described in the text, milk sample 2 (diluted 1:10) or buffer was first
incubated with pepstatin A or buffer, followed by a 2-h incubation with
1,000 pg of HIV-1 IIIb per ml or an SI 492 or NSI 75 isolate, and then
by an inoculation into lymphocyte cultures. The mean level of HIV-1 p24
produced in an experiment in duplicate, with 5 to 10% variability, is
shown.
|
|
HIV-1 growth in MCF7 mammary cancer cells.
The SI 496 isolate
grew in cathepsin D-producing MCF7 cells to an extent similar to that
found in lymphocyte cultures not treated with the protease (Fig.
2). Virus growth in MCF7 cells decreased
when the culture was grown in stripped medium deprived of steroid from
fetal calf serum by treatment with dextran-coated charcoal. We verified
that cell growth was not slowed down in this medium. Since estrogens
have been shown to induce cathepsin D synthesis (14), our
data indicate that replication of the SI 496 isolate in the
CD4-negative MCF7 cells may depend on cathepsin D production.
Curiously, however, virus infection in stripped medium resulted in an
early burst of p24 production, followed by a decrease in production, an
observation which will be discussed. In contrast to the SI 496 variant,
HIV-1 IIIb and the NSI 82 isolate grew very poorly in MCF7 cells. In a
second experiment (not shown), two of three isolates grew in MCF7
cells.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Compared susceptibility of lymphocytes and MCF7 cells to
infection of 106 cells by HIV-1 IIIb, an SI 496 isolate, or
an NSI 82 isolate. Viruses were also inoculated into MCF7 cells which
had been grown for 72 h in stripped medium devoid of estrogens. The
cells remained in this medium after viral infection. The mean of an
experiment in duplicate, with 3 to 10% variability, is shown.
|
|
Expression of HIV-1 mRNA in MCF7 cells.
To ensure that HIV-1
p24 released in the culture supernatant resulted from de novo HIV-1
replication, we looked for intracellular HIV-1 mRNA (Fig.
3). Total mRNA was isolated from
106 cells with the Microfast Track kit (Invitrogen), and
then reverse transcription was performed with a Subscript II kit (Gibco
BRL). PCR on cDNA used the HIV-1 gp120-specific primers 5'-GAA TCT GTA GAA ATT AAT TGT ACA AGA CCC-3' and 5'-TTT TGC TCT ACT AAT GTT ACA ATG
TGC TTG-3', according to Jones et al. (17). After a preliminary denaturing step at 94°C for 3 min, a series of 35 cycles
performed denaturation at 94°C for 1 min, annealing at 63°C for 1 min, and extension at 72°C for 1.5 min. A final cycle lasted for 10 min at 72°C. PCR products run in a 2% agarose gel revealed a 141-bp
DNA fragment. The sequence of this band showed homology with HIV
sequences collected from data bank BIGBEN (accession no. AC U00367).
Fig. 3A shows that viral mRNA was recovered when HIV-1 IIIb was
inoculated into MCF7 cells grown in their cathepsin D-containing
medium, but not when the virus was incubated with cells washed in
phosphate-buffered saline (PBS) (lanes b and c). Infection of these
washed cells did occur when the virus had been preincubated with 2 µg
of cathepsin D per ml or with vaginal wash sample 22 (lanes d and e).
Lane f shows the expression of HIV-1 mRNA in an MCF7 cell line which
had been passed several times after viral infection and then frozen and
subcultured again, indicating that a chronically infected cell line had
been obtained.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Conditions determining whether HIV-1 mRNA was
expressed in MCF7 cells. Cultures were grown for 2 days, reached 80%
confluence, and were incubated at 37°C with 1 ml of conditioned
medium alone (lane a) or containing 1,000 pg of HIV-1 IIIb p24 (lane
b). Three other cultures were incubated in estrogen-free medium plus
HIV-1 IIIb pretreated for 10 min with either buffer (lane c), 2 µg of
cathepsin D per ml (lane d), or vaginal wash sample 22 (lane e). After
a 2-h incubation, cells were washed three times with phosphate-buffered
saline. Samples of 106 cells were immediately harvested
(time, 0 h) while the remaining cultures were grown for 24 h
at 37°C and then collected with EDTA and centrifuged (time, 24 h). Cell pellets were treated with lysing buffer, and total mRNA was
extracted and reverse transcribed. With the cDNA, a specific
amplification of gp120 HIV-1 sequences was performed with primers
described in the text. PCR products were run in a 2% agarose gel. MCF7
cells subcultured for several passages after HIV-1 inoculation were
also tested (lane f). (B) Assay for receptor mRNA specific for CXCR4,
CCR5, and CD4 in PBL (lane g) and in MCF7 cells (lane h).
|
|
Culture samples (conditions were as those for lanes b to e, described
above) collected just after virus absorption (time 0)
did not show any
HIV-1 mRNA expression. Moreover, purified mRNA
treated with RNase
before reverse transcriptase PCR (RT-PCR) did
not show any band on
agarose gel (data not shown). These results
demonstrate the absence of
a significant amount of residual cell
DNA and HIV genomic
RNA.
Receptor expression in MCF7 cells.
We first assayed whether
HIV-1 infection of MCF7 cells could be blocked by anti-CD4 antibody.
Cell monolayers at 80% confluency were grown for 24 h in the
presence of 1 µg of OKT4a monoclonal antibody per ml and then were
infected with HIV-1 IIIb or an SI 496 isolate in the presence of the
same amount of antibody. This treatment did not modify virus growth,
although our previous data showed that it did abolish virus replication
in CD4-positive CEM cells (12). We then explored the nature
of the coreceptor that HIV-1 isolates might use to penetrate MCF7
cells. Aliquots of total mRNA from peripheral blood lymphocytes (PBL)
and from MCF7 cells were reverse transcribed and cDNA sequences were
amplified by PCR with primers specific for CD4, CCR5, and CXCR4,
according to a technique modified from Raport et al. (24)
and previously described (12). cDNA fragments specific for
the three receptors were found in PBL, while only a CXCR4 fragment was
detected in MCF7 cells (Fig. 3B).
Finally, since galactosylceramides have been shown to function as
receptors in some CD4-negative mucosal epithelial cell lines
(
33), we treated MCF7 cells with a monoclonal
anti-galactosylceramide
antibody, which did not modify HIV growth (data
not
shown).
The present data, together with those obtained with vaginal secretions,
indicate that niches in the organism other than blood
may influence the
local HIV-1 population, not only by selection
of genetic variants
(
34) but also by phenotypic modifications.
The importance of
the cleavage of influenza virus hemagglutinin
by respiratory proteases
is well documented (
1).
The implication of cathepsin D in the enhancing effect of milk was
inferred here by the inhibition of the effect by anti-cathepsin
D
antibody and by pepstatin A, but we could only demonstrate the
presence
of procathepsin D in human milk, by affinity chromatography
on
pepstatin A agarose (data not shown), which is in agreement
with
published data (
30). In the bovine milk, procathepsin D
was
the major form present and showed protease activity (
20).
Regarding the cell source of the protease in milk, in vitro cathepsin
D
production does not occur in stationary noncancerous mammary
epithelial
cells (
3), but it might be induced in vivo in cells
of
lactating
glands.
It has been shown (
28) that some cultures of human mammary
epithelial cells support the growth of HIV-1, but factors involved
in
permissiveness were not disclosed. We have identified cathepsin
D as
one of these factors. The finding that the cathepsin D-producing
MCF7
cells could continuously replicate HIV-1 raises the possibility
that
proliferating cells from the lactating gland may be a continuous
source
of HIV-1 in
milk.
When MCF7 cells cultured in steroid-free medium ceased to produce
cathepsin D, the arrest of virus growth was preceded by
a brief burst
of HIV-1 p24 production. This burst may have been
due to the fact that
in the absence of estrogens, synthesis of
the cathepsin D receptor is
reduced (
2,
5,
31), and thus
cathepsin D may transiently
persist in the free
form.
In the mammary epithelial cell line studied here, the receptor used by
HIV-1 isolates could be CXCR4. This would imply that
MCF7 cells might
preferentially replicate lymphotropic or dualtropic
isolates. There are
no data characterizing isolates from breast
milk in the literature. We
found that three of five SI isolates
obtained from blood replicated in
MCF7 while one NSI isolate did
not. Although HIV-1 IIIb produced only
low levels of p24 in the
medium, viral mRNA was detected 24 h
after
infection.
We present here the hypothesis that cathepsin D interaction with HIV-1
gp120 may induce a conformational change similar to
that caused by CD4
(
18) that allows subsequent interaction with
coreceptor
molecules. On the virion, it has been shown that the
binding site to
the second receptor is masked by a V3 loop and
V1/V2 stem
(
32). Rearrangement during gp120-CD4 interaction
appears to
expose the binding site to coreceptors. On the other
hand, it has been
shown that the V3 loop of HIV-1 is cleaved by
cathepsin E, which shares
cleavage sites with cathepsin D (
4).
Such a cleavage might
produce deployment similar to that in a
gp120-CD4
complex.
Viral envelope-CD4 coreceptor structures are potentially good
immunogens, which may lead to vaccines mimicking the natural
in vivo
presentation of the viral gp120 (
19). It would be
interesting
to test whether envelope-cathepsin D-coreceptor structures
could
represent similar
immunogens.
Finally, it should be stressed that our data suggest a possible source
of HIV-1 in the mammary gland but do not deal with
the route of HIV-1
penetration into the infant, which has been
recently discussed
(
6).
 |
ACKNOWLEDGMENTS |
We thank J. Fantini for providing anti-galactosylceramide antibody.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Service de
Génétique Appliquée, Université Libre de
Bruxelles, 12 Rue des Professeurs Jeener et Brachet, B-6041 Gosselies,
Belgium. Phone: 32 2 650 99 01. Fax: 32 2 650 99 00. E-mail:
Kelmessa{at}sga.ulb.ac.be.
 |
REFERENCES |
| 1.
|
Barbey-Morel, C. L.,
T. N. Oeltman, and K. M. Edwards.
1987.
Role of respiratory proteases in infectivity of influenza A virus.
J. Infect. Dis.
155:667-672[Medline].
|
| 2.
|
Capony, F.,
M. Garcia,
J. Capdevielle,
C. Rougeot,
P. Ferrata, and H. Rochefort.
1986.
Purification and first characterization of the secreted and cellular 52-kDa proteins regulated by estrogens in human-breast cancer cells.
Eur. J. Biochem.
161:505-512[Medline].
|
| 3.
|
Capony, F.,
C. Rougeot,
P. Montcourrier,
V. Cavailles,
G. Salazar, and H. Rochefort.
1989.
Increased secretion, altered processing, and glycolysation of pro-cathepsin D in human mammary cancer cells.
Cancer Res.
49:3904-3909[Abstract/Free Full Text].
|
| 4.
|
Clements, G. J.,
M. J. Price-Jones,
P. E. Stephens,
C. Sutton,
T. F. Schultz,
P. R. Clapham,
J. A. McKeating,
M. O. McClure,
S. Thomson,
M. Marsh,
J. Kay,
R. A. Weiss, and J. P. Moore.
1991.
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion.
AIDS Res. Hum. Retrovir.
7:3-16[Medline].
|
| 5.
|
Confort, C.,
H. Rochefort, and F. Vignon.
1995.
Insulin-like growth factors (IGFs) stimulate the release of a1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from MCF7 breast cancer cells.
Endocrinology
136:3759-3766[Abstract].
|
| 6.
|
Coutsoudis, A.,
K. Pillay,
E. Spooner,
L. Kuhn, and H. M. Coovadia.
1999.
Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study.
Lancet
354:471-476[CrossRef][Medline].
|
| 7.
|
Dabis, F.,
P. Msellat,
N. Meda,
C. Welffens-Ekra,
B. You,
O. Manigart,
V. Leroy,
A. Simonon,
M. Cartoux,
P. Combe,
A. Ouangré,
R. Ramon,
O. Ky-Zerbo,
C. Montoho,
R. Salamon,
C. Rouzioux,
P. Vandeperre, and L. Mandelbrot.
1999.
6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial.
Lancet
353:786-792[CrossRef][Medline].
|
| 8.
|
Datta, P.,
J. E. Embree,
J. K. Kreiss,
J. O. Ndinya-Achola,
M. Braddick,
M. Temmerman,
N. J. D. Nagelkerke,
G. Maitha,
K. K. Holmes,
P. Piot,
H. O. Pamba, and F. A. Plummer.
1994.
Mother-to-child transmission of human immunodeficiency virus type 1 report from the Nairobi study.
J. Infect. Dis.
170:1134-1140[Medline].
|
| 9.
|
Defer, M. C.,
B. Dugas,
O. Picard, and C. Damas.
1995.
Impairment of circulating lactoferrin in HIV-1 infection.
Cell. Mol. Biol.
41:417-421[Medline].
|
| 10.
|
de Jong, M. D.,
R. J. de Boer,
F. de Wolf,
N. A. Foudraine,
C. A. B. Boucher,
J. Goudsmit, and J. M. A. Lange.
1997.
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
AIDS
11:F79-F84[CrossRef][Medline].
|
| 11.
|
Ekpini, E. R.,
S. Z. Wiktor,
G. A. Satten,
G. T. Adjorlolo-Johnson,
T. S. Sibailly,
C. Y. Ou,
J. M. Karon,
K. Brattegaard,
J. P. Whittaker,
E. Gnaore,
K. M. De Cock, and A. E. Greenberg.
1997.
Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire.
Lancet
349:1054-1059[CrossRef][Medline].
|
| 12.
|
El Messaoudi, K.,
L. Thiry,
N. Van Tieghem,
C. Liesnard,
Y. Englert,
N. Moguilevsky, and A. Bollen.
1999.
HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions.
AIDS
13:333-339[CrossRef][Medline].
|
| 13.
|
Garcia, F.,
M. Plana,
C. Vidal,
A. Cruceta,
W. A. O'Brien,
G. Pantaleo,
T. Pumarola,
T. Gallart,
J. M. Miro, and J. M. Gatell.
1999.
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
AIDS
13:F79-F86[CrossRef][Medline].
|
| 14.
|
Garcia, M.,
F. Capony,
D. Derocq,
D. Simon,
B. Pau, and H. Rochefort.
1985.
Characterization of monoclonal antibodies to the estrogen-regulated M. 52,000 glycoprotein and their use in MCF7 cells.
Cancer Res.
45:709-716[Abstract/Free Full Text].
|
| 15.
|
Goldman, A. S.,
C. Garza,
B. L. Nichols, and R. M. Goldblum.
1982.
Immunological factors in human milk during the first year of lactation.
J. Pediatr.
100:563-567[CrossRef][Medline].
|
| 16.
|
Harmsen, M. C.,
P. J. Swart,
M. P. de Béthune,
R. Pauwels,
E. De Clercq,
T. H. The, and D. K. F. Meijer.
1995.
Antiviral effects of plasma and milk proteins lactoferrin show potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.
J. Infect. Dis.
172:380-388[Medline].
|
| 17.
|
Jones, J. A. E.,
S. A. Fiscus, and R. Sawanstrom.
1997.
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay.
J. Virol.
71:8750-8758[Abstract].
|
| 18.
|
Kwong, P. D.,
R. Wyatt,
J. Robinson,
R. W. Sweet, and J. Sodroski.
1998.
Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature
393:648-659[CrossRef][Medline].
|
| 19.
|
La Casse, R. A.,
K. E. Follis,
M. Trahey,
J. D. Scarborough,
D. R. Littman, and J. H. Nunberg.
1999.
Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
Science
283:357-362[Abstract/Free Full Text].
|
| 20.
|
Larsen, L. B.,
C. Benfeldt,
L. K. Rasmussen, and T. E. Petersen.
1996.
Bovine milk procathepsin D and cathepsin D: coagulation and milk protein degradation.
J. Dairy Res.
63:119-130[Medline].
|
| 21.
|
Nduati, R. W.,
J. C. John,
B. A. Richardson,
J. Overbaugh,
M. Welch,
J. Ndinya-Achola,
S. Moses,
K. Holmes,
F. Onyango, and J. K. Kreiss.
1995.
Human immunodeficiency virus type-1 infected cells in breast milk: association with immunodepression and vitamin A deficiency.
J. Infect. Dis.
172:1461-1468[Medline].
|
| 22.
|
Newell, M. L.
1998.
Mechanisms and timing of mother-to-child transmission of HIV-1.
AIDS
12:831-837[CrossRef][Medline].
|
| 23.
|
Oxtoby, M. J.
1988.
Human immunodeficiency virus and other viruses in human milk: placing the issue on broader perspectives.
Pediatr. Infect. Dis. J.
7:825-835[Medline].
|
| 24.
|
Raport, C. L.,
J. Gosling,
V. L. Sceickart,
P. W. Gray, and I. F. Charo.
1996.
Molecular cloning and functional characterization of a novel CC chemokine receptor (CCR5) for Rantes, MIP-1b and MIP-1a.
J. Biol. Chem.
271:17161-17166[Abstract/Free Full Text].
|
| 25.
|
Semba, R. D.,
P. G. Miotti,
Y. Lan,
J. D. Chiphangwi,
D. R. Hoover,
G. A. Dallabetta,
L. P. Yang, and A. J. Saah.
1998.
Maternal serum lactoferrin and vertical transmission of HIV.
AIDS
12:331-332[Medline].
|
| 26.
|
Simonon, A.,
F. Lepage, and E. Karita.
1994.
An assessment of the timing of mother-to-child transmission of human immunodeficiency virus type 1 by means of polymerase chain reaction.
J. Acquir. Immune Defic. Syndr.
4:952-957.
|
| 27.
|
Thiry, L.,
S. Sprecher-Goldberger,
T. Jonckheer,
J. Levy,
P. Van de Perre,
P. Henrivaux,
J. Cogniaux-Le Clerc, and N. Clumeck.
1985.
Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers.
Lancet
ii:891-892.
|
| 28.
|
Tonolio, A.,
C. Serra,
P. G. Conaldi,
F. Basolo,
V. Falcone, and A. Dolei.
1995.
Productive HIV-1 infection of normal human mammary epithelial cells.
AIDS
9:859-866[Medline].
|
| 29.
|
Vandeperre, P.,
N. Meda,
M. Cartoux,
V. Leroy, and F. Dabis.
1997.
Late post natal transmission of HIV-1 and early weaning.
Lancet
350:221.
|
| 30.
|
Vetvicka, V.,
J. Vagner,
M. Baudys,
J. Tang,
S. I. Foundling, and M. Fusek.
1993.
Human breast milk contains procathepsin D detection by specific antibodies.
Biochem. Mol. Biol. Int.
30:921-928[Medline].
|
| 31.
|
Vignon, F., and H. Rochefort.
1992.
Interactions of pro-cathepsin D and IGF-II on the mannose-6-phosphate/IGF-II receptor.
Breast Cancer Res. Treat.
22:47-57[CrossRef][Medline].
|
| 32.
|
Wyatt, R.,
P. D. Kwong,
E. Desjardins,
R. W. Sweet,
J. Robinson,
W. A. Hendrickson, and J. G. Sodroski.
1998.
The antigenic structure of the HIV gp120 envelope glycoprotein.
Nature
393:705-711[CrossRef][Medline].
|
| 33.
|
Yahi, N.,
J.-M. Sabatier,
S. Baghdiguian,
F. Gonzalez-Scarano, and J. Fantini.
1995.
Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
J. Virol.
69:320-325[Abstract].
|
| 34.
|
Zhu, T.,
N. A. Wang, and A. Carr.
1996.
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission.
J. Virol.
70:3098-3107[Abstract].
|
Journal of Virology, January 2000, p. 1004-1007, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Moriuchi, M., Moriuchi, H.
(2004). Cell-Type-Dependent Effect of Transforming Growth Factor {beta}, a Major Cytokine in Breast Milk, on Human Immunodeficiency Virus Type 1 Infection of Mammary Epithelial MCF-7 Cells or Macrophages. J. Virol.
78: 13046-13052
[Abstract]
[Full Text]